Current Report Filing (8-k)
December 30 2022 - 5:03PM
Edgar (US Regulatory)
0001601280
false
0001601280
2022-12-30
2022-12-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
———————
FORM 8-K
———————
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 30, 2022
———————
MediXall Group, Inc.
(Exact name of registrant as specified in
its charter)
———————
Nevada |
333-186282 |
33-0864127 |
(State or Other Jurisdiction |
(Commission |
(I.R.S. Employer |
of Incorporation) |
File Number) |
Identification No.) |
2929
East Commercial Blvd., PH-D, Fort Lauderdale, Florida 33308
(Address of Principal Executive Office) (Zip Code)
(954) 440-4678
(Registrant’s telephone number, including area
code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
N/A |
N/A |
N/A |
Indicate by check mark whether the registrant is an emerging growth company
as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth company ☐ |
|
If an emerging growth company, indicate by checkmark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Section 5 - Corporate Governance and Management
Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 30, 2022 MediXall Group,
Inc. (the "Company") announced the resignation of Richard Paul as Chief Financial Officer, effective December 30, 2022. Richard
Paul’s resignation was not a result of a disagreement relating to the registrant’s operations, policies or practices. Richard
Paul’s resignation as Chief Financial Officer is accepted by the board and Mr. Paul will cease to be Chief Financial Officer of
the Corporation and Noel Guillama-Alvarez is elected to serve as Principal Financial Officer of the Company as the Board conducts a hiring process
for a full-time Chief Financial Officer.
Mr. Guillama-Alvarez is 62 years
old. He is a nationally recognized expert on healthcare management and operations, as well as the use of technology in healthcare. Since
1984 he has been Chairman of Guillama, Inc., a strategic operations management consulting company in healthcare, technology, and a wide
range of projects including medical facilities, commercial complexes and infrastructure facilities. He holds several patents and is creator
of over a dozen patents currently before the USPTO in a variety of areas. Mr. Guillama-Alvarez is a co-founder of Quantum Innovations, Inc. and
its parent company, The Quantum Group, Inc., and has been Chief Executive Officer and President since its inception. Prior to this, Mr.
Guillama-Alvarez was the Founder, Chairman, President and Chief Executive Officer of Metropolitan Health Networks, Inc. (NYSE:MDF) from its inception
in 1996 to 2000 when he left Metropolitan to develop Quantum, a new breed healthcare company designed to provide multifaceted solutions
industry wide. He is the Past Chair (Currently Director) of the Florida International University Foundation, a direct support organization
of Florida International University, managing a $230 million endowment. Mr. Guillama-Alvarez is a graduate of executive and leadership programs
at Massachusetts Institute of Technology’s, University of Georgia and Florida International University.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
|
Description |
99.1 |
|
Letter of Resignation |
104 |
|
Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MediXall Group Inc. |
|
|
|
|
|
|
Dated: December 30, 2022 |
By: |
/s/ Travis Jackson |
|
Name: |
Travis Jackson |
|
Title: |
Chief Executive Officer |
MediXall (CE) (USOTC:MDXL)
Historical Stock Chart
From Apr 2024 to May 2024
MediXall (CE) (USOTC:MDXL)
Historical Stock Chart
From May 2023 to May 2024